JP2018538000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538000A5 JP2018538000A5 JP2018533097A JP2018533097A JP2018538000A5 JP 2018538000 A5 JP2018538000 A5 JP 2018538000A5 JP 2018533097 A JP2018533097 A JP 2018533097A JP 2018533097 A JP2018533097 A JP 2018533097A JP 2018538000 A5 JP2018538000 A5 JP 2018538000A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- human
- recombinant
- seq
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003527 eukaryotic cell Anatomy 0.000 claims 20
- 238000000034 method Methods 0.000 claims 15
- 210000000349 chromosome Anatomy 0.000 claims 10
- 238000003776 cleavage reaction Methods 0.000 claims 10
- 230000007017 scission Effects 0.000 claims 10
- 150000007523 nucleic acids Chemical group 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 210000002459 blastocyst Anatomy 0.000 claims 4
- 210000001671 embryonic stem cell Anatomy 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 239000013607 AAV vector Substances 0.000 claims 2
- 108020004511 Recombinant DNA Proteins 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000006780 non-homologous end joining Effects 0.000 claims 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021031458A JP7203873B2 (ja) | 2015-12-23 | 2021-03-01 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
| JP2022209145A JP2023052095A (ja) | 2015-12-23 | 2022-12-27 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562387318P | 2015-12-23 | 2015-12-23 | |
| US62/387,318 | 2015-12-23 | ||
| US201662416513P | 2016-11-02 | 2016-11-02 | |
| US62/416,513 | 2016-11-02 | ||
| PCT/US2016/068289 WO2017112859A1 (en) | 2015-12-23 | 2016-12-22 | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021031458A Division JP7203873B2 (ja) | 2015-12-23 | 2021-03-01 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018538000A JP2018538000A (ja) | 2018-12-27 |
| JP2018538000A5 true JP2018538000A5 (OSRAM) | 2020-02-06 |
| JP6846429B2 JP6846429B2 (ja) | 2021-03-24 |
Family
ID=57794384
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018533097A Active JP6846429B2 (ja) | 2015-12-23 | 2016-12-22 | ヒトβ−２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
| JP2021031458A Active JP7203873B2 (ja) | 2015-12-23 | 2021-03-01 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
| JP2022209145A Pending JP2023052095A (ja) | 2015-12-23 | 2022-12-27 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021031458A Active JP7203873B2 (ja) | 2015-12-23 | 2021-03-01 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
| JP2022209145A Pending JP2023052095A (ja) | 2015-12-23 | 2022-12-27 | ヒトβ－２ミクログロブリン遺伝子に見られる認識配列を有する操作されたメガヌクレアーゼ |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20190017075A1 (OSRAM) |
| EP (2) | EP3394253B1 (OSRAM) |
| JP (3) | JP6846429B2 (OSRAM) |
| AU (2) | AU2016379393B2 (OSRAM) |
| CA (1) | CA3009637A1 (OSRAM) |
| ES (1) | ES2901000T3 (OSRAM) |
| WO (1) | WO2017112859A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3359660T3 (en) | 2015-10-05 | 2020-02-17 | Prec Biosciences Inc | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| AU2016333898B2 (en) | 2015-10-05 | 2020-11-12 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene |
| WO2017112859A1 (en) * | 2015-12-23 | 2017-06-29 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| BR112019007450A2 (pt) | 2016-10-14 | 2020-07-07 | Precision Biosciences, Inc. | meganucleases modificadas específicas para sequências de reconhecimento no genoma do vírus da hepatite b |
| WO2018208837A1 (en) * | 2017-05-08 | 2018-11-15 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
| JP7356354B2 (ja) | 2017-05-12 | 2023-10-04 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用 |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| WO2019005957A1 (en) | 2017-06-30 | 2019-01-03 | Precision Biosciences, Inc. | GENETICALLY MODIFIED T CELLS COMPRISING A MODIFIED INTRON IN THE ALPHA T CELL RECEPTOR GENE |
| TW201923073A (zh) * | 2017-11-20 | 2019-06-16 | 新加坡商泰莎治療私人有限公司 | 經修飾之k562細胞 |
| SG11202003864XA (en) * | 2017-12-13 | 2020-07-29 | Janssen Biotech Inc | Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| JP7304888B2 (ja) | 2018-04-12 | 2023-07-07 | プレシジョン バイオサイエンシズ，インク． | ヒトｔ細胞受容体アルファ定常領域遺伝子に特異性を有する最適化された操作されたヌクレアーゼ |
| EP3790629A1 (en) | 2018-05-11 | 2021-03-17 | CRISPR Therapeutics AG | Methods and compositions for treating cancer |
| WO2020146807A1 (en) * | 2019-01-10 | 2020-07-16 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified transferrin gene |
| IL299249B2 (en) | 2019-04-03 | 2024-01-01 | Prec Biosciences Inc | Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) |
| US20220204994A1 (en) | 2019-04-05 | 2022-06-30 | Precision Biosciences, Inc. | Methods of preparing populations of genetically-modified immune cells |
| CN113939319A (zh) | 2019-04-30 | 2022-01-14 | 克里斯珀医疗股份公司 | 靶向cd19的基因工程化t细胞针对b细胞恶性肿瘤的同种异体细胞疗法 |
| JP2022531459A (ja) | 2019-05-07 | 2022-07-06 | プレシジョン バイオサイエンシズ，インク． | 認識配列に対する、操作されたメガヌクレアーゼの最適化 |
| ES3022990T3 (en) | 2019-12-06 | 2025-05-29 | Prec Biosciences Inc | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| US20230183664A1 (en) | 2020-05-11 | 2023-06-15 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
| WO2022040582A1 (en) * | 2020-08-21 | 2022-02-24 | Precision Biosciences, Inc. | Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene |
| EP4221836A4 (en) * | 2020-09-29 | 2025-02-19 | Neuexcell Therapeutics Inc. | NEUROD1 AND DLX2 VECTOR |
| CA3197178A1 (en) * | 2020-09-29 | 2022-04-07 | NeuExcell Therapeutics Inc. | Neurod1 combination vector |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| EP4419660A2 (en) * | 2021-10-19 | 2024-08-28 | Precision BioSciences, Inc. | Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency |
| WO2024236547A1 (en) | 2023-05-18 | 2024-11-21 | Inceptor Bio, Llc | Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof |
| WO2025046513A1 (en) | 2023-08-29 | 2025-03-06 | Inceptor Bio, Llc | Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US6015832A (en) | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
| US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
| US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
| ES2602184T3 (es) | 2005-10-18 | 2017-02-20 | Precision Biosciences | Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas |
| WO2008102199A1 (en) | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| EP2215223B1 (en) | 2007-10-31 | 2013-05-01 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| EP2329017A2 (en) * | 2008-08-04 | 2011-06-08 | Cellectis | Novel method to generate meganucleases with altered characteristics |
| WO2012167192A2 (en) | 2011-06-01 | 2012-12-06 | Precision Biosciences, Inc. | Methods and products for producing engineered mammalian cell lines with amplified transgenes |
| ES2782125T3 (es) * | 2014-03-11 | 2020-09-10 | Cellectis | Método para generar linfocitos T compatibles para trasplante alogénico |
| WO2017112859A1 (en) | 2015-12-23 | 2017-06-29 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
-
2016
- 2016-12-22 WO PCT/US2016/068289 patent/WO2017112859A1/en not_active Ceased
- 2016-12-22 CA CA3009637A patent/CA3009637A1/en active Pending
- 2016-12-22 US US16/065,756 patent/US20190017075A1/en not_active Abandoned
- 2016-12-22 JP JP2018533097A patent/JP6846429B2/ja active Active
- 2016-12-22 AU AU2016379393A patent/AU2016379393B2/en active Active
- 2016-12-22 EP EP16825979.4A patent/EP3394253B1/en active Active
- 2016-12-22 ES ES16825979T patent/ES2901000T3/es active Active
- 2016-12-22 EP EP21193857.6A patent/EP3988655A3/en not_active Withdrawn
-
2020
- 2020-10-19 US US17/074,135 patent/US20210032664A1/en not_active Abandoned
-
2021
- 2021-03-01 JP JP2021031458A patent/JP7203873B2/ja active Active
-
2022
- 2022-12-27 JP JP2022209145A patent/JP2023052095A/ja active Pending
-
2023
- 2023-04-03 AU AU2023202035A patent/AU2023202035A1/en not_active Abandoned
- 2023-10-20 US US18/491,484 patent/US20240052373A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018538000A5 (OSRAM) | ||
| US10858662B2 (en) | Genome editing with split Cas9 expressed from two vectors | |
| IL277883B2 (en) | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene | |
| CN105308184B (zh) | 大鼠基因组的靶向修饰 | |
| ES2784754T3 (es) | Métodos y composiciones para modificar un locus objetivo | |
| JP2018536390A5 (OSRAM) | ||
| NZ773169A (en) | Universal donor cells | |
| JP2017018125A5 (OSRAM) | ||
| JP2021502085A5 (OSRAM) | ||
| Mizuno-Iijima et al. | Efficient production of large deletion and gene fragment knock-in mice mediated by genome editing with Cas9-mouse Cdt1 in mouse zygotes | |
| IN2015DN01785A (OSRAM) | ||
| IL274179B2 (en) | Targeted replacement of endogenous T cell receptors | |
| NZ705675A (en) | Engineered transgene integration platform (etip) for gene targeting and trait stacking | |
| JP2016165307A5 (OSRAM) | ||
| JP2017513479A5 (OSRAM) | ||
| JP2012522501A5 (OSRAM) | ||
| IL309801A (en) | Use of protein domains interacting with the nucleosome to enhance targeted genome modification | |
| JP2020505025A5 (OSRAM) | ||
| JP2016518142A5 (OSRAM) | ||
| CN108690845A (zh) | 基因组编辑系统和方法 | |
| JP2018535663A5 (OSRAM) | ||
| JP2018531624A5 (OSRAM) | ||
| JP2018525979A5 (OSRAM) | ||
| CA2933433A1 (en) | Methods and compositions for the targeted modification of a genome | |
| KR20240055863A (ko) | 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물 |